Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-25

Study Completion Date

2017-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and effectiveness of the Jetstream Atherectomy System for the treatment of Japanese patients with symptomatic occlusive atherosclerotic lesions in native superficial femoral artery (SFA) and/or proximal popliteal arteries (PPA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME II)

NCT03847233

Peripheral Arterial Disease

COMPLETED NA

Jetstream in Treatment of Occlusive Atherosclerotic Lesions in the SFA and/or PPA

NCT03455855

Atherosclerosis

COMPLETED NA

The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

NCT03551496

Critical Limb Ischemia

COMPLETED PHASE3

Evaluating the Safety and Efficacy of the G-stream® Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

NCT05780359

Peripheral Artery Disease

RECRUITING NA

JetStream Atherectomy for the Treatment of In-stent Restenosis

NCT02730234

Femoropopliteal In-stent Restenosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, multicenter, single-arm trial evaluating the safety and efficacy of the Jetstream Atherectomy System in the treatment of symptomatic occlusive atherosclerotic lesions ≤150 mm in length located in the femoropopliteal arteries in subjects with symptoms classified as Rutherford categories 2-4.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Jetstream Atherectomy System

Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention

Group Type EXPERIMENTAL

Jetstream Atherectomy System

Intervention Type DEVICE

A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Jetstream Atherectomy System

A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2-4
* Stenotic, restenotic or occlusive lesion(s) located in the native SFA and/or PPA of which meet all of the following criteria:

* Calcified lesions with degree of stenosis ≥70% or occlusions
* Guidewire must cross lesion(s) within the true lumen, without a sub-intimal course
* Vessel diameter ≥3.0 mm and ≤6.0 mm
* Total lesion length (or series of lesions) ≤150mm
* Target lesion located at least 3 cm above the inferior edge of the femur by visual estimate
* Patent infrapopliteal and popliteal artery

Exclusion Criteria

* Target lesion/vessel with in-stent restenosis
* Target lesion/vessel previously treated with drug-coated balloon \<12 months prior to the procedure
* Target lesion/vessel previously treated with any stent placement, atherectomy, laser or other debulking devices prior to the procedure
* Subjects who have undergone surgery or endovascular of the SFA/PPA in the target vessel to treat atherosclerotic disease within 3 months prior to the index procedure
* Use of drug-coated devices, atherectomy, laser or other debulking devices other than the Jetstream System, chronic total occlusion (CTO) devices or cutting balloon, Angioscore or similar devices in the target limb SFA/PPA during the index procedure
* History of major amputation in the target limb
* Subject has a history of coagulopathy or hypercoagulable bleeding disorder
* Subject with untreatable hemorrhagic disease or platelet count \<80,000mm3 or \>600,000mm3 as baseline assessment.
* Concomitant renal failure with a serum creatinine \>2.0 mg/dL
* Receiving dialysis or immunosuppressant therapy
* History of myocardial infarction, or stroke/cerebrovascular accident (CVA) within 6 months prior to study enrollment
* Unstable angina pectoris at the time of the enrollment
* Septicemia at the time of enrollment
* Presence of other hemodynamically significant outflow lesions in the target limb requiring a planned surgical intervention or endovascular procedure within 30 days after the index procedure
* Presence of aneurysm in the target vessel
* Acute ischemia and/or acute thrombosis of the SFA/PPA prior to the index procedure
* Perforated vessel as evidenced by extravasation of contrast media prior to the index procedure

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No